FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2540409119> ?p ?o ?g. }

• W2540409119 endingPage "72867" @default.
• W2540409119 startingPage "72860" @default.
• W2540409119 abstract "// Elizabeth Shurell 1, * , Maria E. Vergara-Lluri 2, * , Yunfeng Li 3 , Joseph G. Crompton 1 , Arun Singh 4 , Nicholas Bernthal 5 , Hong Wu 3 , Fritz C. Eilber 1 , Sarah M. Dry 2 1 Division of Surgical Oncology, University of California, Los Angeles, CA 90095, USA 2 Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA 90095, USA 3 Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095, USA 4 Department of Hematology/Oncology, University of California, Los Angeles, CA 90095, USA 5 Department of Orthopaedic Surgery, University of California, Los Angeles, CA 90095, USA * Co-first author Correspondence to: Fritz C. Eilber, email: fceilber@mednet.ucla.edu Keywords: NY-ESO-1, sarcoma, MPNST, liposarcoma, immunotherapy Received: July 28, 2016      Accepted: September 09, 2016      Published: September 17, 2016 ABSTRACT Background: Immunotherapy targeting cancer-testis antigen NY-ESO-1 shows promise for tumors with poor response to chemoradiation. Malignant peripheral nerve sheath tumors (MPNSTs) and liposarcomas (LPS) are chemoresistant and have few effective treatment options. Materials Methods: Using a comprehensive tissue microarray (TMA) of both benign and malignant tumors in primary, recurrent, and metastatic samples, we examined NY-ESO-1 expression in peripheral nerve sheath tumor (PNST) and adipocytic tumors. The PNST TMA included 42 MPNSTs (spontaneous n = 26, NF1-associated n = 16), 35 neurofibromas (spontaneous n = 22, NF-1 associated n = 13), 11 schwannomas, and 18 normal nerves. The LPS TMA included 48 well-differentiated/dedifferentiated (WD/DD) LPS, 13 myxoid/round cell LPS, 3 pleomorphic LPS, 8 lipomas, 1 myelolipoma, and 3 normal adipocytic tissue samples. Stained in triplicate, NY-ESO-1 intensity and density were scored. Results: NY-ESO-1 expression was exclusive to malignant tumors. 100% of myxoid/round cell LPS demonstrated NY-ESO-1 expression, while only 6% of WD/DD LPS showed protein expression, one of which was WD LPS. Of MPNST, 4/26 (15%) spontaneous and 2/16 (12%) NF1-associated MPNSTs demonstrated NY-ESO-1 expression. Strong NY-ESO-1 expression was observed in myxoid/round cell and dedifferentiated LPS, and MPNST in primary, neoadjuvant, and metastatic settings. Conclusions: We found higher prevalence of NY-ESO-1 expression in MPNSTs than previously reported, highlighting a subset of MPNST patients who may benefit from immunotherapy. This study expands our understanding of NY-ESO-1 in WD/DD LPS and is the first demonstration of staining in a WD LPS and metastatic/recurrent myxoid/round cell LPS. These results suggest immunotherapy targeting NY-ESO-1 may benefit patients with aggressive tumors resistant to conventional therapy." @default.
• W2540409119 created "2016-11-04" @default.
• W2540409119 creator A5002439302 @default.
• W2540409119 creator A5005260055 @default.
• W2540409119 creator A5043007782 @default.
• W2540409119 creator A5044756037 @default.
• W2540409119 creator A5048977799 @default.
• W2540409119 creator A5070052371 @default.
• W2540409119 creator A5077449490 @default.
• W2540409119 creator A5083557120 @default.
• W2540409119 creator A5089368547 @default.
• W2540409119 date "2016-09-17" @default.
• W2540409119 modified "2023-09-23" @default.
• W2540409119 title "Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma" @default.
• W2540409119 cites W1572718168 @default.
• W2540409119 cites W1979936799 @default.
• W2540409119 cites W1986592841 @default.
• W2540409119 cites W1996539839 @default.
• W2540409119 cites W2008597053 @default.
• W2540409119 cites W2011380060 @default.
• W2540409119 cites W2016334273 @default.
• W2540409119 cites W2033994846 @default.
• W2540409119 cites W2041497714 @default.
• W2540409119 cites W2042174530 @default.
• W2540409119 cites W2071825091 @default.
• W2540409119 cites W2076701855 @default.
• W2540409119 cites W2080401629 @default.
• W2540409119 cites W2082197151 @default.
• W2540409119 cites W2097943307 @default.
• W2540409119 cites W2102339709 @default.
• W2540409119 cites W2105371674 @default.
• W2540409119 cites W2126316295 @default.
• W2540409119 cites W2127734125 @default.
• W2540409119 cites W2129288285 @default.
• W2540409119 cites W2130184077 @default.
• W2540409119 cites W2131544979 @default.
• W2540409119 cites W2141745968 @default.
• W2540409119 cites W2153712501 @default.
• W2540409119 cites W2165119413 @default.
• W2540409119 cites W2306887830 @default.
• W2540409119 doi "https://doi.org/10.18632/oncotarget.12096" @default.
• W2540409119 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5341949" @default.
• W2540409119 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27655679" @default.
• W2540409119 hasPublicationYear "2016" @default.
• W2540409119 type Work @default.
• W2540409119 sameAs 2540409119 @default.
• W2540409119 citedByCount "15" @default.
• W2540409119 countsByYear W25404091192016 @default.
• W2540409119 countsByYear W25404091192017 @default.
• W2540409119 countsByYear W25404091192018 @default.
• W2540409119 countsByYear W25404091192019 @default.
• W2540409119 countsByYear W25404091192020 @default.
• W2540409119 countsByYear W25404091192021 @default.
• W2540409119 countsByYear W25404091192022 @default.
• W2540409119 countsByYear W25404091192023 @default.
• W2540409119 crossrefType "journal-article" @default.
• W2540409119 hasAuthorship W2540409119A5002439302 @default.
• W2540409119 hasAuthorship W2540409119A5005260055 @default.
• W2540409119 hasAuthorship W2540409119A5043007782 @default.
• W2540409119 hasAuthorship W2540409119A5044756037 @default.
• W2540409119 hasAuthorship W2540409119A5048977799 @default.
• W2540409119 hasAuthorship W2540409119A5070052371 @default.
• W2540409119 hasAuthorship W2540409119A5077449490 @default.
• W2540409119 hasAuthorship W2540409119A5083557120 @default.
• W2540409119 hasAuthorship W2540409119A5089368547 @default.
• W2540409119 hasBestOaLocation W25404091191 @default.
• W2540409119 hasConcept C121608353 @default.
• W2540409119 hasConcept C126322002 @default.
• W2540409119 hasConcept C142724271 @default.
• W2540409119 hasConcept C193270364 @default.
• W2540409119 hasConcept C204232928 @default.
• W2540409119 hasConcept C2778173781 @default.
• W2540409119 hasConcept C2778256501 @default.
• W2540409119 hasConcept C2779568860 @default.
• W2540409119 hasConcept C2781225692 @default.
• W2540409119 hasConcept C502942594 @default.
• W2540409119 hasConcept C71924100 @default.
• W2540409119 hasConceptScore W2540409119C121608353 @default.
• W2540409119 hasConceptScore W2540409119C126322002 @default.
• W2540409119 hasConceptScore W2540409119C142724271 @default.
• W2540409119 hasConceptScore W2540409119C193270364 @default.
• W2540409119 hasConceptScore W2540409119C204232928 @default.
• W2540409119 hasConceptScore W2540409119C2778173781 @default.
• W2540409119 hasConceptScore W2540409119C2778256501 @default.
• W2540409119 hasConceptScore W2540409119C2779568860 @default.
• W2540409119 hasConceptScore W2540409119C2781225692 @default.
• W2540409119 hasConceptScore W2540409119C502942594 @default.
• W2540409119 hasConceptScore W2540409119C71924100 @default.
• W2540409119 hasIssue "45" @default.
• W2540409119 hasLocation W25404091191 @default.
• W2540409119 hasLocation W25404091192 @default.
• W2540409119 hasLocation W25404091193 @default.
• W2540409119 hasLocation W25404091194 @default.
• W2540409119 hasLocation W25404091195 @default.
• W2540409119 hasOpenAccess W2540409119 @default.
• W2540409119 hasPrimaryLocation W25404091191 @default.
• W2540409119 hasRelatedWork W2020585594 @default.
• W2540409119 hasRelatedWork W2111409713 @default.

• next